Primary Peritoneal Carcinoma Recruiting Phase 1 / 2 Trials for Anlotinib (DB11885)

IndicationStatusPhase
DBCOND0028874 (Primary Peritoneal Carcinoma)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02584478Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)Treatment